← Back

Financiere de Tubize SA

Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company based in Belgium. UCB focuses on the discovery and development of treatments for patients with diseases affecting the immune or central nervous system. Financière de Tubize SA was founded in 1928 and is based in Brussels, Belgium.

Price · split & dividend adjusted
News & notes moving 0D53.LSE
Biotech & Genomic Medicine

UCB Reports Record First-Half 2026 Sales, Raises Full-Year Guidance

UCB SA delivered record first-half 2026 results, with total net sales growing 23% to EUR4.1 billion and adjusted EBITDA surging 68% to EUR1.7 billion. The strong performance was driven by its five growth drivers, which now account for over 50% of revenue, led by BIMZELX net sales doubling to EUR1.5 billion. The company upgraded its full-year 2026 guidance, now expecting low-teens to mid-teens revenue growth and mid-teens to low-20s EBITDA growth at constant exchange rates. Core EPS nearly doubled to EUR6.84, while the effective tax rate stood at 15% and net financial debt reached EUR2.8 billion. UCB also raised BIMZELX's peak sales potential to at least EUR7 billion, supported by four head-to-head superiority trials, and highlighted a long-term growth runway with no major loss of exclusivity until 2033.
GuruFocus·49dRead more →